<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353077</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-SCC-000</org_study_id>
    <nct_id>NCT03353077</nct_id>
  </id_info>
  <brief_title>Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)</brief_title>
  <official_title>A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters on Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpha Tau Medical LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpha Tau Medical LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A unique approach for Skin Squamous Cell Carcinoma (SCC) treatment employing intratumoral&#xD;
      diffusing alpha radiation emitter device&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective study, assessing the safety and effectiveness of intratumoral&#xD;
      alpha radiation mediated treatment with Alpha DaRT seeds for the treatment of Skin Squamous&#xD;
      Cell Carcinoma (SCC) tumors.&#xD;
&#xD;
      Treatment will be delivered through radioactive sources (Alpha DaRT seeds) inserted into the&#xD;
      tumors in the skin. This approach combines the advantages of local intratumoral irradiation&#xD;
      of the tumor, as used in conventional brachytherapy, with the power of the alpha radiation&#xD;
      emitting atoms, that will be introduced in quantities considerably lower than radiation&#xD;
      therapy already used in patients.&#xD;
&#xD;
      Lesions with histopathological diagnosis of squamous cell carcinoma will be studied.&#xD;
&#xD;
      Reduction in tumor size 30-45 days after DaRT insertion will be assessed. Safety will be&#xD;
      assessed by the incidence, severity and frequency of all Adverse Events (AE).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 21, 2017</start_date>
  <completion_date type="Actual">July 14, 2019</completion_date>
  <primary_completion_date type="Actual">July 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>30-45 days post seed insertion</time_frame>
    <description>The incidence, severity and frequency of all Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in Tumor size</measure>
    <time_frame>30-45 days post seed insertion</time_frame>
    <description>The reduction in tumor size 30-45 days after DaRT insertion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of NecroticTissue</measure>
    <time_frame>30-45 days post seed insertion</time_frame>
    <description>Percent of necrotic tissue in the tumor 30-45 days after DaRT insertion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Skin Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Alpha DaRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpha DaRT Seeds, Diffusing alpha-emitters Radiation Therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)</intervention_name>
    <description>An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.</description>
    <arm_group_label>Alpha DaRT</arm_group_label>
    <other_name>DaRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with histopathological confirmation of skin squamous cell carcinoma before&#xD;
             surgical removal of the tumor.&#xD;
&#xD;
          -  Subjects with a tumor size ≤ 5 centimeters in the longest diameter (lesions without&#xD;
             nodal spread).&#xD;
&#xD;
          -  Subjects' age is over 18 years old.&#xD;
&#xD;
          -  Subjects' ECOG Performance Status Scale is ≤ 2.&#xD;
&#xD;
          -  Subjects' life expectancy is more than 6 months.&#xD;
&#xD;
          -  Female subjects of childbearing age will have evidence of negative pregnancy test.&#xD;
&#xD;
          -  Subjects are willing to sign an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a tumor with a maximal diameter &gt; 5 centimeters.&#xD;
&#xD;
          -  Subject has an ulcerative lesion.&#xD;
&#xD;
          -  Subject has a tumor of Keratoacanthoma histology.&#xD;
&#xD;
          -  Subjects' ECOG Performance Status Scale is ≥ 3.&#xD;
&#xD;
          -  Patients with moribund diseases, e.g., autoimmune diseases, vasculitis, etc.&#xD;
&#xD;
          -  Patients under immunosuppressive and/or corticosteroid treatment.&#xD;
&#xD;
          -  Volunteers that participated in other studies in the past 30 days that might affect&#xD;
             the evaluation of response or toxicity of DaRT.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Subjects not willing to sign an informed consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin SCC</keyword>
  <keyword>Skin Carcinoma, Squamous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

